Jaap Goudsmit

USPTO Granted Patents = 20 (Patent Applications = 8)

CIPO Patents = 6 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 4.5

ph-index = 8

Forward Citations = 217(Granted Patents)

Location History:

Leiden, NL (2019 - 2020)
Amsterdam, NL (1996 - 2024)

Company Filing History:

5 out of 115

Janssen Vaccines & Prevention B.v.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Janssen Pharmaceuticals, Inc.

patents

7. 2 out of 1,217

The United States of America As Represented by the Department of Health

patents

8. 1 out of 68

International Aids Vaccine Initiative

where one patent can have more than one assignee

Years Active: 1996-2024

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11958889 - Compositions of phosphorylated tau peptides and uses thereof (2024-04-16),

2. 11591377 - Heterologous administration of tau vaccines (2023-02-28),

3. 11472869 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2022-10-18),

4. 11124552 - Compositions of phosphorylated tau peptides and uses thereof (2021-09-21),

5. 10562963 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2020-02-18),

6. 10400034 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2019-09-03),

7. 10301379 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2019-05-28),

8. 9701718 - Adenovirus serotype 26 and serotype 35 filovirus vaccines (2017-07-11),

9. 9074262 - Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1 (2015-07-07),

10. 9012618 - Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures (2015-04-21),

11. 8697352 - Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1 (2014-04-15),

12. 8106170 - Compositions against SARS-coronavirus and uses thereof (2012-01-31),

13. 8101739 - Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector (2012-01-24),

14. 7696330 - Binding molecules against SARS-coronavirus and uses thereof (2010-04-13),

15. 7425437 - Vaccines against West Nile Virus (2008-09-16),

Title: Jaap Goudsmit - Pioneering Inventor from Amsterdam

Introduction: Jaap Goudsmit is a distinguished inventor hailing from Amsterdam, Netherlands, known for his groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Jaap Goudsmit holds several patents in the areas of vaccine development, infectious diseases, and immunology, showcasing his innovative approach to solving complex health challenges.

Career Highlights: With a career spanning over three decades, Goudsmit has held prominent positions in leading research institutions and biotech companies, where he has spearheaded numerous projects that have revolutionized the medical landscape.

Collaborations: Throughout his career, Jaap Goudsmit has collaborated with top scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge exchange in the scientific community.

Conclusion: Jaap Goudsmit's relentless pursuit of scientific excellence and his passion for innovation have solidified his reputation as a visionary inventor in the field of biotechnology, leaving an indelible mark on the world of medical research.

This text is generated by artificial intelligence and may not be accurate.